Taipei, Taiwan, 06 January 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced a significant milestone with the approval of VAZKEPA® (Icosapent Ethyl) by the Health Sciences Authority (“HSA”) of Singapore, marking the first entry into Southeast Asia. VAZKEPA® is the first prescription treatment in which icosapent ethyl (IPE), a highly purified form of eicosapentaenoic acid (EPA), is the sole active ingredient, developed to reduce cardiovascular events in high-risk patients.
HSA has granted approval for VAZKEPA® as an adjunct to maximally tolerated statin therapy to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150mg/dL [≥1.7 mmol/L]) and established cardiovascular disease, or diabetes mellitus with 2 or more additional risk factors for cardiovascular disease. Lotus, in its long-term exclusive partnership with Amarin Corporation plc (NASDAQ:AMRN), welcomes its first VAZKEPA® entry in Southeast Asia where many patients stand to benefit from this novel therapeutic option.
In 2024, almost 1 out of 3 deaths in Singapore were due to cardiovascular disease (heart disease or stroke)1. Every day, about 22 people in Singapore die of cardiovascular disease1. Additionally, the recent National Population Health Survey 2024 revealed that about 1 in 3 Singapore residents have hyperlipidemia and/or hypertension2.
Petar Vazharov, Chief Executive Officer of Lotus, commented, "We are pleased to advance our collaboration with Amarin through the approval of VAZKEPA® in Singapore. This milestone reflects our continued focus on bringing innovative therapies to patients with unmet needs. It also demonstrates our ability to effectively leverage the commercial capabilities we have built across key Asian markets to support timely access to new treatment options."
------------------------------------------------------------------------------------
- Singapore Heart Foundation. Heart Disease Statistics. [Available online at: https://www.myheart.org.sg/health/heart-disease-statistics/ (cited December 23, 2025; accessed December 23, 2025)
- Ministry of Health Newsroom Press Release. [Available online at: https://www.moh.gov.sg/newsroom/national-population-health-survey-2024-shows-singaporeans-are-adopting-healthier-lifestyles---but-rising-obesity-is-a-concern/ (cited December 23, 2025; accessed December 23, 2025)
About Amarin
Amarin is a global pharmaceutical company committed to reducing the cardiovascular disease (CVD) burden for patients and communities and to advancing the science of cardiovascular health around the world. We own and support a global branded product approved by multiple regulatory authorities based on a track record of proven efficacy and safety and backed by robust clinical trial evidence. Our commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally, through a syndicate of reputable and well-established partners with significant geographic expertise, covering over 90 markets worldwide. Our success is driven by a dedicated, talented, and highly skilled team of experts passionate about the fight against the world’s leading cause of death, CVD.
About Lotus
Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with a global presence, focused on commercializing both novel and generic pharmaceuticals to provide patients with better, safer, and more accessible medicines. The company boasts a best-in-class R&D and manufacturing platform in Asia, certified by leading regulatory authorities around the world, including the US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA. Lotus has established partnerships in nearly every major global market, including the U.S., Europe, Japan, China, and Brazil. The company is currently developing and registering over 100 strategically selected pharmaceutical projects across Asia and the U.S., with more than 250 commercial products. Lotus invests in a diversified portfolio, consisting of high-barrier oncology, complex generics, 505(b)2, NCEs, and biosimilars, through both internal R&D investments and licensing-in partnerships to strengthen its portfolio competitiveness.
Media Inquiries:
Yihsuan Kuo, Investor Relations Assistant Manager
Jeffrey Tsang, Head of Investor Relations and Corporate Communications
+886 2 2700 5908
investor@lotuspharm.com